158 related articles for article (PubMed ID: 35263200)
1. RNA-seq and integrated network analysis reveals the hub genes and key pathway of paclitaxel inhibition on Adriamycin resistant diffuse large B cell lymphoma cells.
Hong H; Luo B; Qin Y; Li S; Peng Z
Bioengineered; 2022 Mar; 13(3):7607-7621. PubMed ID: 35263200
[TBL] [Abstract][Full Text] [Related]
2. Sirt1 gene confers Adriamycin resistance in DLBCL via activating the PCG-1α mitochondrial metabolic pathway.
Zhou Z; Ma D; Li P; Wang P; Liu P; Wei D; Wang J; Qin Z; Fang Q; Wang J
Aging (Albany NY); 2020 Jun; 12(12):11364-11385. PubMed ID: 32570218
[TBL] [Abstract][Full Text] [Related]
3. The effects of the long non-coding RNA MALAT-1 regulated autophagy-related signaling pathway on chemotherapy resistance in diffuse large B-cell lymphoma.
Li LJ; Chai Y; Guo XJ; Chu SL; Zhang LS
Biomed Pharmacother; 2017 May; 89():939-948. PubMed ID: 28292022
[TBL] [Abstract][Full Text] [Related]
4. Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database.
Luo B; Gu YY; Wang XD; Chen G; Peng ZG
Pathol Res Pract; 2018 Nov; 214(11):1854-1867. PubMed ID: 30244948
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Qing K; Jin Z; Xu Z; Wang W; Li X; Zhang Y; Wang L; Zhu H; Xiang R; Wu S; Li R; Jiang G; Xue K; Li J
Chemotherapy; 2022; 67(1):12-23. PubMed ID: 34844236
[TBL] [Abstract][Full Text] [Related]
6. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
7. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
8. Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma.
Maxwell SA; Cherry EM; Bayless KJ
Leuk Lymphoma; 2011 May; 52(5):849-64. PubMed ID: 21323512
[TBL] [Abstract][Full Text] [Related]
9. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
Wang S; Sun L
Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line.
Han J; Tang Y; Zhong M; Wu W
Mol Med Rep; 2019 Dec; 20(6):5064-5074. PubMed ID: 31638226
[TBL] [Abstract][Full Text] [Related]
11. Development of taxane-containing chemotherapy of doxorubicin-resistant diffuse large B-cell lymphoma.
Wu L; Wang J; Li Y; Zuo L; Zhang Z; Ouyang J; Fan J; Li H
Anticancer Drugs; 2014 Aug; 25(7):826-31. PubMed ID: 24423982
[TBL] [Abstract][Full Text] [Related]
12. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J
Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212
[TBL] [Abstract][Full Text] [Related]
13. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide DNA methylation and RNA-seq analyses identify genes and pathways associated with doxorubicin resistance in a canine diffuse large B-cell lymphoma cell line.
Hsu CH; Tomiyasu H; Liao CH; Lin CS
PLoS One; 2021; 16(5):e0250013. PubMed ID: 33961622
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
16. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
17. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.
Song YH; Zhong MZ; Gan PP; Yi PY; Tang YH; Liu YP; Jiang JQ; Li L
Tumour Biol; 2014 Dec; 35(12):11809-17. PubMed ID: 25344211
[TBL] [Abstract][Full Text] [Related]
18. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen.
Maxwell SA; Li Z; Jaya D; Ballard S; Ferrell J; Fu H
J Biol Chem; 2009 Aug; 284(33):22379-22389. PubMed ID: 19525224
[TBL] [Abstract][Full Text] [Related]
19. TAK1 is a druggable kinase for diffuse large B-cell lymphoma.
Wu Y; Yang R; Ming Y; Xu Y; Chen H; Yao M; Chen X; Mao R; Fan Y
Cell Biochem Funct; 2019 Apr; 37(3):153-160. PubMed ID: 30907011
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]